Medyssey's posterior lumbar interbody fusion system gets 510(k) clearance
This article was originally published in Clinica
The LP Cage spinal implant developed by Korean company Medyssey Spine has received 510(k) clearance from the US FDA. The device is indicated for use in lumbar interbody fusion procedures in skeletally mature patients with degenerative disc disease at one or two contiguous levels from L2-S1 vertebrae in the lower spine. It is currently undergoing a limited market release; full commercial launch is planned for the fourth quarter of 2011. The Seoul-based company also announced an 84% increase in US sales in the first quarter of 2011 over the same period in 2010. It says it is on course to achieve its eighth consecutive year of market share growth in the global spine market.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.